A phase I/II trial of PXD101 [belinostat] in patients with unresectable hepatocellular carcinoma with pharmacokinetic and pharmacodynamic evaluation.

Trial Profile

A phase I/II trial of PXD101 [belinostat] in patients with unresectable hepatocellular carcinoma with pharmacokinetic and pharmacodynamic evaluation.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Belinostat (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2012 Results presented at the ASCO Gastrointestinal Cancers Symposium (ASCO-GCS)
    • 13 Sep 2011 Status changed from recruiting to completed, according to results reported in a TopoTarget media release.
    • 13 Sep 2011 Results reported in a TopoTarget media release, and will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top